PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- staging of a known recurrence
- Patients over 18 years
- initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
- ...
- staging of a known recurrence
- Patients over 18 years
- initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
- Patient who have signed an informed consent
- Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)
- Patient affiliated or beneficiary of regime of social security of a Member State of the European community
- Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
- Search of the primary tumor, especially in the case of the inaugural discovery of metastases
- Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Exclusion Criteria
- Persons placed under judicial protection
- Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
- Pregnant or lactating woman
- ...
- Persons placed under judicial protection
- Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
- Pregnant or lactating woman
- Patient unable to give their free and informed consent
- Patient with another evolutive cancer disease and/or treated for less than 5 years
Summary
- Conditions
- Neuroendocrine Tumors
- Type
- Observational
- Design
- Observational Model: Case-Only
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- staging of a known recurrence
- Patients over 18 years
- initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
- ...
- staging of a known recurrence
- Patients over 18 years
- initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
- Patient who have signed an informed consent
- Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)
- Patient affiliated or beneficiary of regime of social security of a Member State of the European community
- Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
- Search of the primary tumor, especially in the case of the inaugural discovery of metastases
- Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Exclusion Criteria
- Persons placed under judicial protection
- Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
- Pregnant or lactating woman
- ...
- Persons placed under judicial protection
- Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
- Pregnant or lactating woman
- Patient unable to give their free and informed consent
- Patient with another evolutive cancer disease and/or treated for less than 5 years
Tracking Information
- NCT #
- NCT02134639
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Philippe FERNANDEZ, Professor University Hospital, Bordeaux
- Philippe FERNANDEZ, Professor University Hospital, Bordeaux